Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems

Halis K. Akturk; Tadej Battelino; Javier Castañeda; Arcelia Arrieta; Tim van den Heuvel; Ohad Cohen

doi:10.1089/dia.2023.0432

Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems

Halis K. Akturk, Tadej Battelino, Javier Castañeda, Arcelia Arrieta, Tim van den Heuvel, Ohad Cohen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

The concept of maintaining blood glucose levels within the 70–180 mg/dL range, known as time-in-range, has raised questions regarding its representation of true physiological euglycemia. Some have speculated that focusing on the time spent within the 70–140 mg/dL range, introduced as time in tight range (TITR) through the International Consensus statement, could serve as a more precise metric for assessing normoglycemia in individuals with type 1 diabetes. This article delves into the current status of TITR as an emerging marker and explores how advanced hybrid closed-loop systems may offer a promising avenue for achieving this higher level of glycemic control.

Original language	English
Pages (from-to)	102-106
Number of pages	5
Journal	Diabetes Technology and Therapeutics
Volume	26
DOIs	https://doi.org/10.1089/dia.2023.0432
State	Published - 1 Mar 2024
Externally published	Yes

Funding

Funders	Funder number
Medtronic

Keywords

Automated insulin delivery
Closed-loop
Glucose control
Insulin pump
Insulin therapy
MiniMed
Time in tight range

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1089/dia.2023.0432

Cite this

@article{a80c92901339478ea288d1e2b81217cd,

title = "Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems",

abstract = "The concept of maintaining blood glucose levels within the 70–180 mg/dL range, known as time-in-range, has raised questions regarding its representation of true physiological euglycemia. Some have speculated that focusing on the time spent within the 70–140 mg/dL range, introduced as time in tight range (TITR) through the International Consensus statement, could serve as a more precise metric for assessing normoglycemia in individuals with type 1 diabetes. This article delves into the current status of TITR as an emerging marker and explores how advanced hybrid closed-loop systems may offer a promising avenue for achieving this higher level of glycemic control.",

keywords = "Automated insulin delivery, Closed-loop, Glucose control, Insulin pump, Insulin therapy, MiniMed, Time in tight range",

author = "Akturk, {Halis K.} and Tadej Battelino and Javier Casta{\~n}eda and Arcelia Arrieta and Heuvel, {Tim van den} and Ohad Cohen",

year = "2024",

month = mar,

day = "1",

doi = "10.1089/dia.2023.0432",

language = "אנגלית",

volume = "26",

pages = "102--106",

journal = "Diabetes Technology and Therapeutics",

issn = "1520-9156",

publisher = "Mary Ann Liebert Inc.",

}

TY - JOUR

T1 - Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems

AU - Akturk, Halis K.

AU - Battelino, Tadej

AU - Castañeda, Javier

AU - Arrieta, Arcelia

AU - Heuvel, Tim van den

AU - Cohen, Ohad

PY - 2024/3/1

Y1 - 2024/3/1

N2 - The concept of maintaining blood glucose levels within the 70–180 mg/dL range, known as time-in-range, has raised questions regarding its representation of true physiological euglycemia. Some have speculated that focusing on the time spent within the 70–140 mg/dL range, introduced as time in tight range (TITR) through the International Consensus statement, could serve as a more precise metric for assessing normoglycemia in individuals with type 1 diabetes. This article delves into the current status of TITR as an emerging marker and explores how advanced hybrid closed-loop systems may offer a promising avenue for achieving this higher level of glycemic control.

AB - The concept of maintaining blood glucose levels within the 70–180 mg/dL range, known as time-in-range, has raised questions regarding its representation of true physiological euglycemia. Some have speculated that focusing on the time spent within the 70–140 mg/dL range, introduced as time in tight range (TITR) through the International Consensus statement, could serve as a more precise metric for assessing normoglycemia in individuals with type 1 diabetes. This article delves into the current status of TITR as an emerging marker and explores how advanced hybrid closed-loop systems may offer a promising avenue for achieving this higher level of glycemic control.

KW - Automated insulin delivery

KW - Closed-loop

KW - Glucose control

KW - Insulin pump

KW - Insulin therapy

KW - MiniMed

KW - Time in tight range

UR - http://www.scopus.com/inward/record.url?scp=85185625882&partnerID=8YFLogxK

U2 - 10.1089/dia.2023.0432

DO - 10.1089/dia.2023.0432

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 38377325

AN - SCOPUS:85185625882

SN - 1520-9156

VL - 26

SP - 102

EP - 106

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

ER -

Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems

Abstract

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this